Virtus LifeSci Biotech Products ETF (BBP)
ARCA ARCA Primary 
SGX Summary
BBP Chart
BBP: The Biotech ETF That Filters For FDA-Approved Drugs
Virtus Biotech ETF (BBP) is rated a buy for its focused exposure to FDA-approved biotech firms and strong recent outperformance. BBP's equal-weight, quarterly rebalancing strategy efficiently captures upside from breakout holdings like MRNA while reducing speculative risk. Rising sector deal activity and GLP-1 market expansion underpin a favorable outlook for BBP despite macro headwinds like higher interest rates.
Virtus LifeSci Biotech Products ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MC mike Chen Byrne Asset Management LLC | 142 | $11,347.22 | $13,756.59 | $2,409.37 | 21.23% |
 Christopher C. Powers Farther Finance Advisors, LLC | 23 | $1,946.51 | $2,158.95 | $212.44 | 10.91% |
Virtus LifeSci Biotech Products ETF (BBP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Virtus LifeSci Biotech Products ETF ever had a stock split?
Virtus LifeSci Biotech Products ETF Profile
| ARCA Exchange | US Country |
Overview
The described fund is focused on investing a significant portion of its assets, not less than 80%, into the common stocks of biotechnology companies that are listed on U.S. exchanges and have received approval from the U.S. Food and Drug Administration (FDA) for at least one of their drug therapies. This investment strategy aligns with the goal of tracking the index that represents the performance of these U.S. biotechnology firms, ensuring that the fund participates in the sector's potential growth driven by successful drug developments and regulatory approvals.
Products and Services
- Investment in Biotechnology Stocks
The fund dedicates at least 80% of its assets to stocks of U.S. exchange-listed biotechnology companies that have successfully brought a drug therapy to market with FDA approval. This focus on companies with market-approved therapies mitigates some of the risks associated with the biotechnology sector, as these companies have already cleared significant regulatory hurdles and have a product generating revenue.
- Tracking the Performance of an Index
The objective is to mirror the performance of an index that measures the success of U.S. biotechnology firms with at least one FDA-approved drug therapy. This approach allows investors to gain exposure to the biotechnology industry's growth potential through a diversified portfolio of stocks, reducing the investment risk typically associated with individual company performances.
